

# Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors

NCT07490236

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Hebei Medical University Fourth Hospital
Enrollment	100 participants

## Key Eligibility Criteria

---

### Inclusion (1)

- patients for whom primary prophylaxis with trilaciclib is indicated per Model A will receive primary prophylactic treatment.

### Exclusion (1)

- patients for whom primary prophylaxis with trilaciclib is not indicated per Model A will receive secondary prophylaxis according to protocol.

## Locations (1 total)

---

The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China